Latest news
Anixa Biosciences announces first case of stable disease for three months in ovarian cancer CAR-T clinical trial
Anixa Biosciences, a biotechnology company focused on the treatment and prevention of cancer, has announced that a patient in...
Vial doses first patient with asthma in phase 1b study of Vial’s IL-13 x TSLP, a bispecific antibody designed for twice-yearly dosing
Vial, a clinical-stage biotechnology company, has dosed the first patient in its phase 1b clinical study of Vial's IL-13...
Lundbeck presents phase 1b data for Lu AF28996 in advanced Parkinson’s disease, as phase 2 trial begins
H Lundbeck has announced results from an open-label phase 1b trial evaluating Lu AF28996, a novel, investigational, oral prodrug...
AbbVie and Genmab announce epcoritamab in combination with R-CHOP demonstrates significant improvement in progression-free survival versus R-CHOP in patients with newly diagnosed diffuse large...
AbbVie has announced positive topline results from the phase 3 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody...
New partnership expands UK trial access for potential world-first vaccine against killer infection
Jane Lyons is the first person dosed in this study
Thousands of older people across the UK stand to benefit from...
Allegro’s Hydrocelin significantly improves knee osteoarthritis pain and function in clinical trial
Allegro NV, a biomedical company developing a transformative nanotechnology treatment for osteoarthritis, has announced statistically significant improvements in pain...
ENA Respiratory begins part B dosing in INNA-051 phase 2a community study designed to protect against symptomatic viral respiratory infections
ENA Respiratory, a clinical-stage pharmaceutical company developing host defence enhancers for the prevention of complications associated with respiratory viral infections in at-risk...
Just – Evotec Biologics advances US Department of War antibodies against orthopoxvirus into phase 1 clinical studies
Evotec SE has announced the initiation of a phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal...
Novartis remibrutinib significantly reduces relapse rates and shows favourable safety profile in phase 3 RMS trials
Novartis has announced positive topline results from its phase 3 trials of remibrutinib in relapsing multiple sclerosis.
Remibrutinib, a highly...
GSK to advance mRNA seasonal flu vaccine candidate to phase 3 following positive phase 2 data
GSK presented positive phase 2 data for its mRNA seasonal influenza (flu) vaccine candidate at the Options XIII Conference...
New phase 3b data on Eli Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults...
Eli Lilly and Company (NYSE: LLY) has announced 52-week results from Together-PsO and Together-PsA, two novel open-label phase 3b clinical trials...
Acoramidis demonstrates reversal of cardiac structural disease progression and functional decline and significantly increases days alive and free from hospitalisation in ATTR-CM
BridgeBio Pharma has presented new analyses from the phase 3 study of Attruby (acoramidis) in transthyretin amyloid cardiomyopathy (ATTR-CM),...
Tezspire demonstrates positive phase 3 results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
Amgen and AstraZeneca have announced positive top-line results from the phase 3 trial of Tezspire (tezepelumab-ekko) in patients living with...
Late-breaking data for Abbott’s Tactiflex Duo Ablation Catheter reveal positive outcomes for treating complex AFib cases
Abbott, the global healthcare leader, has announced new late-breaking 12-month data from the FlexPulse Global IDE study that show...
Teva announces positive topline results from phase 2a study in celiac disease for its anti-IL-15 antibody, further validating its pipeline-in-a-product potential
Teva Pharmaceutical has announced positive topline results from an ongoing phase 2a study of TEV ‘408, an investigational anti-interleukin-15...
Raziel Therapeutics and Fosun Pharma announce positive phase 3 results for RZL-012 in submental fat reduction, clearing the path to a China NDA filing
Raziel Therapeutics has announced positive results from its phase 3 registration trial in China evaluating RZL-012 for the reduction...
AbbVie announces positive topline results from the phase 3 trial showing Etentamig significantly improved response rate and progression-free survival in patients with relapsed/refractory multiple...
AbbVie has announced positive topline results from a phase 3 study evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager,...
African Bundibugyo ebolavirus vaccine candidate advanced to clinical trials
Leading African biopharmaceutical company Minapharm Group, headquartered in Egypt with subsidiaries in Berlin, will receive up to US$16.5 million from...
NRG Therapeutics presents data on lead clinical asset NRG5051 confirming novel disease-modifying approach to ALS
NRG, an innovative clinical stage neuroscience company targeting a novel mechanism to restore mitochondrial dysfunction in neurodegenerative diseases, today...
VarmX enrols first participant in global phase 3 trial evaluating VMX‑C001 in urgent surgery
VarmX, a biotech company developing innovative approaches to bypass direct oral anticoagulants targeting activated factor Xa (FXa inhibitors), enrolled the first...
Novo Nordisk provides update on a phase 3 trial in people with ASCVD, CKD and inflammation
Novo Nordiskhas announced headline results from the cardiovascular outcomes from a phase 3 trial.
While ziltivekimab demonstrated target engagement and...
Kodiak Sciences completes enrolment in first pivotal cohort in the phase 3 trial of KSI-101 for macular oedema secondary to inflammation and reaffirms topline...
Kodiak Sciences Inc. has completed enrolment of the first 300-patient cohort in its clinical trial, supporting pivotal analysis of...
Ractigen Therapeutics announces completion of enrolment and first dosing in phase 2 clinical trial of RAG-17 for SOD1-ALS
Ractigen Therapeutics, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics, has completed patient enrolment and initial dosing across all...
BioVie announces topline results of phase 2 trial of bezisterim in early Parkinson’s disease
BioVie Inc., a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, has announced results from the...
Vivani Medical announces successful dosing of all participants in a phase 1 trial evaluating NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight...
Vivani Medical, Inc., has announced full enrolment and successful initial dosing of all participants in its phase 1 trial...
- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -
Popular